Trial
NCT02963610
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Fox Chase Cancer Center
Collaborators
Merck Sharp & Dohme LLC; Celgene
Condition
Relapsed or Refractory Solid Tumors
Intervention
Lenalidomide
Why stopped
Study terminated prematurely due to funding/support being withdrawn by grantor
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-30